scholarly journals Chronic Hepatitis C in Western Canada: A Survey of Practice Patterns among Gastroenterologists in Alberta and British Columbia

2014 ◽  
Vol 28 (1) ◽  
pp. e1-e4 ◽  
Author(s):  
Rohit Pai ◽  
Alnoor Ramji ◽  
Samuel S Lee ◽  
Winnie W Wong ◽  
Eric M Yoshida

OBJECTIVE: To survey gastroenterologists in British Columbia and Alberta with regard to awareness of chronic hepatitis C virus (HCV) management and practice patterns among physicians who treat and do not treat HCV-infected patients.METHODS: An anonymous two-page mail survey was distributed to actively practicing adult gastroenterologists in British Columbia and Alberta. Among physicians who treated HCV patients, respondents answered assessment of fibrosis pretreatment, measurement of rapid virological response, prescription of protease inhibitors (PIs), barriers to using these agents and referral patterns. For those who did not treat HCV, referral of patients for treatment and to whom was assessed.RESULTS: Seventy-seven of 166 individuals completed the survey (46% response rate). Most (49%) practiced in academic or large community (42%) settings. Chronic liver disease comprised <25% of individual practice in 71%. Forty-eight (62%) treated HCV and two-thirds prescribed a PI. Barriers to prescription included unfamiliarity (six of 16), lack of allied health (five of 16) and few suitable patients (seven of 16). Pretreatment liver biopsy was performed by 33% (16 of 48) and 69% (33 of 48) used noninvasive measures. Rapid virological response was measured in 83% (40 of 48). Referral patterns changed in 46% (22 of 48) of physicians who treated HCV. All respondents who did not treat HCV referred patients for consideration, with 90% (26 of 29) made to hepatologists.CONCLUSIONS: Chronic liver disease comprised <25% of practice in the majority of surveyed respondents. Among those who treated HCV, one-third have not prescribed a PI. Barriers to prescription and referral pattern changes are noted by those currently treating patients with HCV infection.

2004 ◽  
Vol 41 (3) ◽  
pp. 180-184 ◽  
Author(s):  
Angelo Alves de Mattos ◽  
Eliana Buksztejn Gomes ◽  
Cristiane Valle Tovo ◽  
Cláudio Osmar Pereira Alexandre ◽  
José Oscar dos Reis Remião

BACKGROUND: Considering the immunosuppression of patients with chronic liver disease, their response to vaccination is discussed in literature. AIMS: To evaluate the response of hepatitis B vaccine in patients with chronic hepatitis C virus infection. METHODS: This is a prospective study in which 85 patients with chronic hepatitis C virus infection (46.8 ± 9.4 years, 44.7% males) and 46 healthy adults (36.7 ± 11.1 years; 39.1% males) were evaluated. Confirmation of hepatitis C virus was obtained by the technique of polymerase chain reaction. Viral load was determined by the branched DNA method in 74 patients, and genotype was determined by sequencing in 73 patients. All patients and healthy adults received three doses of Engerix B® vaccine IM (at 0, 30 and 180 days). Serological responses to the vaccine were divided into three categories: seroprotection, when anti-HBs was >100 mUI/mL; seroconversion, when anti-HBs was 10-99 mUI/mL, and non-reagent, when anti-HBs was <10 mUI/mL. RESULTS: The response of hepatitis B vaccine as determined 1 month following dose 3 was seroprotection in 37.7%, seroconversion in 17.6% and non-reagent in 44.7% among patients and 84.8%, 13.0%, 2.2%, respectively in healthy adults. The number of non-reagent responses was significantly higher among those patients with chronic liver disease. Sixty-five patients with chronic hepatitis were compared to 20 compensated cirrhotic patients in concern to the response to vaccine, but no difference was found. The response to vaccine in patients with genotypes 2 or 3 (n = 40) was better than in those with genotype 1 (n = 33). Response was not related to serum HCV-RNA concentration. CONCLUSION: The number of non-responders was higher in patients with chronic hepatitis C virus infection, irrespective of histological status and viral load. It is suggested that such patients should receive a double dose of vaccine, particularly the ones with genotype 1.


Hepatology ◽  
2008 ◽  
Vol 47 (6) ◽  
pp. 1884-1893 ◽  
Author(s):  
Ming-Lung Yu ◽  
Chia-Yen Dai ◽  
Jee-Fu Huang ◽  
Chang-Fu Chiu ◽  
Yi-Hsin C. Yang ◽  
...  

Hepatology ◽  
1997 ◽  
Vol 25 (5) ◽  
pp. 1271-1275 ◽  
Author(s):  
M W Fried ◽  
Y E Khudyakov ◽  
G A Smallwood ◽  
M Cong ◽  
B Nichols ◽  
...  

2012 ◽  
Vol 17 (5) ◽  
pp. 823-831 ◽  
Author(s):  
Salvatore Petta ◽  
Donatella Ferraro ◽  
Calogero Cammà ◽  
Daniela Cabibi ◽  
Antonietta Di Cristina ◽  
...  

2001 ◽  
Vol 195 (4) ◽  
pp. 473-481 ◽  
Author(s):  
Mimoun Nejjari ◽  
Anne Couvelard ◽  
Jean-Fran�ois Mosnier ◽  
Alain Moreau ◽  
G�rard Feldmann ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document